Bilirubin has antioxidant properties and may protect against atherosclerosis and coronary heart disease (CHD). Further, in patients with metabolic syndrome, hyperbilirubinemia is associated with attenuation of insulin resistance. The aim of the present study was to determine the relationship between serum bilirubin concentration and coronary endothelial function in overweight patients. 
and attenuates insulin resistance in patients with metabolic syndrome 7) . Further, low serum concentrations of bilirubin are associated with endothelial dysfunction 6) and an increased risk of CHD 8, 9) and metabolic syndrome 10, 11) . Endothelial dysfunction is an early pivotal event in the development, progression, and manifestation of atherosclerosis 12, 13) . Further, chronic systemic inflammation plays a major pathologic role in metabolic syndrome
Introduction
Bilirubin prevents the oxidation of low-density lipoprotein-cholesterol (LDL-C) [1] [2] [3] , reduces the risk of atherosclerosis and coronary heart disease (CHD) [4] [5] [6] , tion and impaired fibrinolysis [14] [15] [16] ; however, the relationship among serum bilirubin, inflammatory markers, and coronary endothelial function remains unclear.
Aim
The aim of the present study was to determine the relationship between serum bilirubin concentration and coronary endothelial function and to identify the metabolic characteristics of participants that may modify the impact of serum bilirubin concentration on endothelial function.
Methods

Study Population
A total of 107 consecutive patients (age, 61 13 years), who had been referred to Kagoshima University Hospital for cardiac catheterization to exclude coronary artery disease from January 2000 to March 2008, were considered for enrollment in this study. Patients were divided into two groups according to body mass index (BMI) 15, 16) : an overweight group (BMI ≥ 25; n 36) and a normal weight group (BMI 25; n 71). In this study, the overweight group contained pre-obese patients (BMI ≥ 25-30) as well as obese patients (BMI ≥ 30) 17, 18) . Angiographic inclusion criteria were: 1) angiographically smooth arteries; 2) mild irregularities, 30% lumen diameter stenosis by visual assessment in any major conduit vessel; and 3) proximal coronary arteries 2.0 mm in diameter 19) . Patients with a history of previous myocardial infarction, previous coronary revascularization, valvular heart disease, variant angina, cardiomyopathy, myocarditis, or high serum bilirubin concentration with liver dysfunction were excluded from this study.
Long-acting nitrates, calcium channel blocking agents, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), andadrenergic blockers were withheld for 48 hours before the study to allow for the assessment of baseline coronary physiology.
Written informed consent was obtained from all patients after the purpose, nature, and potential risks of the study were explained to the subjects in accordance with guidelines established by the Committee for the Protection of Human Subjects in our institution. Our institutional ethics committee reviewed and approved the study protocol.
Study Protocol
Diagnostic coronary angiography was performed using a 6F Judkins catheter with a standard femoral percutaneous approach. Five thousand units of heparin were administered at the beginning of the procedure. Non-ionic contrast material was used for all patients. No nitroglycerin was given prior to the diagnostic procedure.
Coronary artery response to papaverine and nitroglycerin was studied according to previous reports 20, 21) . After control coronary angiograms, interventions were performed as follows: 1) a bolus of papaverine (an endothelium-independent vasodilator in resistance coronary arteries) (12.5 mg/5 mL) was injected through a catheter; 2) a bolus of nitroglycerin (an endothelium-independent vasodilator in conduit coronary arteries) (200 g/5 mL) was administered. Drugs were infused at least 5 minutes apart. Coronary arteriography was performed before and 1 minute after injection of papaverine and after administration of nitroglycerin. Arterial blood pressure and heart rate were monitored continuously and recorded. Measurements obtained during steady state conditions were used as control values for later analysis.
Assessment of Coronary Vasoreactivity
Coronary endothelium-dependent function was evaluated by assessing the change in coronary artery diameter (CAD) in response to papaverine [percent change in flow-mediated dilatation (%FMD)] 22) . Endothelium-independent vasodilation of the conduit coronary artery was assessed by measuring the percent increase of CAD in response to nitroglycerin (%NTG) 20, 21) .
Quantitative Coronary Angiographic Images
Technically suitable single-plane angiograms were selected for computer analysis. Quantitative coronary angiographic images (DBAC-1000; MID Corporation, Fukuoka, Japan) were recorded using validated densitometric analysis, as previously reported 23) . An end-diastolic still frame at each infusion (baseline, papaverine and nitroglycerin) was selected from the angiographic sequence. Endothelium-dependent and -independent vasodilation of the conduit coronary artery was estimated by measuring the luminal diameter. Measurements were performed by experienced observers who were unaware of the coronary vascular reactivity tests.
Baseline Measurements and Biochemical Analysis
A diagnosis of hypertension was based on systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg, or current treatment with antihypertensive drugs. Diabetes was defined on the basis of a fasting plasma glucose level ≥ 126 mg/dL, HbA1c level ≥ 6.5%, or the use of oral hypoglycemic agents or insulin. Dyslipidemia was defined on the basis of a fasting plasma LDL-C ≥ 140 mg/dL, triglycerides (TG) ≥ 150 mg/dL, or active use of lipid-lowering medication. Cigarette smoking and the menstruation status were determined by self-reporting. BMI was calculated as weight in kilograms divided by the square of height in meters (kg/m 2 ) 17) . Blood samples were obtained from subjects in the fasting state. Serum total bilirubin, direct bilirubin, LDL-C, high density lipoprotein-cholesterol (HDL-C) and TG values were measured using enzymatic methods (Roche Diagnostics Co., Ltd., Basel, Switzerland), implemented in an autoanalyzer (Modular Analytics, Roche Diagnostics Co., Ltd.). High-sensitivity CRP was measured by latex-enhanced nephelometry (Denka Seiken Co., Ltd., Tokyo, Japan). Fasting plasma glucose (FPG) was measured by the glucose oxidase method (GAO3U; A&T Corp., Yokohama, Japan) 24) . Immunoreactive insulin (IRI) was determined by a specific enzyme immunoassay with various reagents (TOSOH Co., Ltd., Yamaguchi, Japan). HbA1C was assessed by the turbidimetric immunoassay method. Insulin resistance was evaluated by the homeostasis model assessment insulin resistance (HOMA-IR) index calculated as follows: FPG (mg/dL) IRI ( U/ mL)/405 25) .
Statistical Analysis
Statistical analysis was performed using Stat View Version 5.0 software. Values are expressed as the means SDs. Before statistical analysis, normal distribution and homogeneity of the variances were tested. Parameters that did not fulfill these tests (total bilirubin, hs-CRP, TG, and HOMA-IR) were log transformed. Comparisons between the two groups were performed using Student's regression analysis unpaired t test. Comparisons of risk factors and drugs between groups were performed using Pearson's chi-square test. All explanatory variables, including log-transformed total bilirubin, log-transformed hs-CRP, HDL-C, LDL-C, log-transformed TG, log-transformed HOMA-IR, mean blood pressure, age and BMI, were used as parameters for coronary vasoreactivity in both Pearson's correlation coefficient analysis and simple linear regression. Statistical analysis of parallelism in linear regression was employed to compare the slopes of the simple regression 26) . Predictive factors for total bilirubin were determined using multiple regression analysis. A p value 0.05 was considered significant.
Results
Patient Characteristics
A total of 107 patients were evaluated in this study. Patient characteristics are summarized in Table 1 . Mean age was not significantly different when comparing the two groups. BMI, systolic, diastolic and mean blood pressures were significantly higher in the overweight group than in the normal weight group. Coronary risk factors were also similar when comparing the two groups, except for the prevalence of dyslipidemia, which was significantly higher in the overweight group than in the normal weight group. There was no significant difference between the two groups in the frequency of the use of cardiac medications.
Biochemical measurement characteristics are shown in Table 2 . LDL-C, IRI and HOMA-IR were significantly higher in the overweight group than in the normal weight group.
Relationship between Coronary Artery Reactivity and Total Bilirubin
The relationship between %FMD and total bili- rubin is illustrated in Fig. 1 . Univariate analysis revealed that %FMD was positively correlated with log-transformed total bilirubin in the overweight group (r 0.38, p 0.05). By contrast, there was no correlation between %FMD and total bilirubin in the normal weight group. The relationship between %FMD and other risk factor variables in the overweight group is summarized in Table 3 . %FMD did not correlate with any variables other than the bilirubin level. The relationship between %FMD and other risk factor variables in the normal weight group is presented in Table 4 . %FMD did not correlate with any variables. %NTG was not significantly correlated with total bilirubin in the overweight or normal weight group (Fig. 2) . In the overweight group, we also compared %FMD and %NTG based on the value of logtransformed total bilirubin [lower bilirubin patients (log-transformed total bilirubin 0.18, n 15); higher bilirubin patients (log-transformed total bilirubin ≥ 0.18, n 21)]. %FMD was significantly lower NTG, endothelium-independent vasodilation induced by nitroglycerin; T-bil, total bilirubin (Fig. 3) . These results suggest that coronary endothelial function was impaired in overweight patients with lower bilirubin levels. Furthermore, %FMD in overweight patients with higher bilirubin levels was comparable to %FMD in normal weight patients, irrespective of whether they had lower or higher bilirubin levels (13.0 12.4% vs. 10.3 11.4% and 10.7 9.9%, respectively; p NS).
Parameters Contributing to Total Bilirubin
In the overweight group, log-transformed total bilirubin was positively correlated with HDL-C (r 0.30, p 0.05) and was inversely correlated with log-transformed hs-CRP and log-transformed HOMA-IR (r 0.45, p 0.01; r 0.45, p 0.05, respectively) ( Table 5) . Log-transformed total bilirubin did not correlate with LDL-C, log-transformed TG, mean BP, age, BMI, or gender ( Table 5 ).
In the normal weight group, log-transformed total bilirubin was inversely correlated with logtransformed HOMA-IR and age (r 0.40, p 0.01; r 0.26, p 0.05, respectively) ( Table 6) . Although there was an inverse correlation between total bilirubin and HOMA-IR in both groups, there was no significant difference in the regression coefficient when comparing the groups (p 0.29). In addition, logtransformed total bilirubin did not correlate with logtransformed hs-CRP, HDL-C, LDL-C, log-transformed TG, mean BP, BMI, or gender ( Table 6 ).
Multivariate analysis revealed that log-transformed hs-CRP was the only independent predictor of log-transformed total bilirubin in the overweight group (p 0.05) ( Table 5) . By contrast, no predictor of log-transformed total bilirubin was identified in the normal weight group (Table 6) .
Further, we compared hs-CRP between the lower and higher bilirubin groups in the overweight and normal weight groups. In the overweight group, hs-CRP was significantly higher in the lower bilirubin group than in the higher bilirubin group (0.56 0.86 mg/dL vs. 0.12 0.12 mg/dL; p 0.05).
Discussion
The present study demonstrated that %FMD was positively correlated with log-transformed total bilirubin in the overweight group but not in the normal weight group, suggesting that elevated bilirubin levels are associated with favorable coronary artery endothelial function in overweight patients. %FMD did not correlate with any risk factor variables other A B than bilirubin. Furthermore, log-transformed total bilirubin was significantly correlated with log-transformed hs-CRP, HOMA-IR, and HDL-C. Among these parameters, hs-CRP was the only independent factor that correlated with total bilirubin. Several studies have noted an inverse relationship between the presence of CHD and total bilirubin. Hopkins et al. 5) showed that higher serum bilirubin is associated with a decreased risk for CHD. This reduction was independent of other known CHD risk and covariates. The apparent protective effects of bilirubin were of a similar magnitude as HDL-C. Schwertner et al. 8) indicated that low bilirubin concentration is associated with the presence of CHD. These and other investigators found that plasma bilirubin correlated inversely with several known risk factors for CHD, such as smoking, LDL-C, diabetes and obesity, and correlated directly with HDL-C 27, 28) .
Relationship between Coronary Endothelial Function and Total Bilirubin
Erdogan et al. 6) used analysis of forearm blood flow by strain-gauge plethysmography to demonstrate that serum total bilirubin was independently related to the vasodilator response to reactive hyperemia. Anderson et al. 29) suggested that endothelial dysfunction in the brachial artery correlated with coronary endothelial dysfunction. Their reports did not indicate whether the correlation between serum total bilirubin and endothelial function was similar when comparing 30) , it is clinically different from the occlusive disease that affects the coronary circulation. For these reasons, our study was designed to investigate the more specific association between serum total bilirubin and %FMD in the coronary artery.
In this study, %FMD correlated with total bilirubin only in overweight patients, and %FMD was significantly lower in the lower than higher bilirubin group in overweight patients. Moreover, %FMD in overweight patients with higher total bilirubin was comparable to that in normal weight patients irrespective of total bilirubin. These results show that bilirubin may be protective against atherosclerosis in overweight patients, possibly via the promotion of endothelial function.
Several studies have documented that exposure to oxidative stress is greater in overweight patients than normal weight patients, which means that coronary endothelial function may be more easily impaired in overweight patients 31, 32) ; however, data from the present study suggest that high bilirubin levels may be protective against coronary endothelial dysfunction in overweight patients, although the same effect may not hold true in normal weight patients.
Relationship between Total Bilirubin and Metabolic Syndrome
In our study, serum total bilirubin was inversely associated with HOMA-IR in both weight groups. There was no significant difference in the regression coefficient when comparing the two groups.
Previous studies 7, 33) demonstrated that serum total bilirubin was inversely associated with insulin resistance in children and adolescents with metabolic syndrome and in young adults, possibly via its anti-oxidative effect or via the effect of its metabolic pathway (biliverdin reductase cycle) on insulin signaling [34] [35] [36] . Giral et al. 37) . demonstrated that patients with metabolic syndrome had a lower level of serum bilirubin that patients without metabolic syndrome. Our data showed no significant difference in total bilirubin between overweight and normal weight patients. By contrast, BMI, prevalence of hypertension, LDL-C, IRI, and HOMA-IR were significantly higher in overweight than normal weight patients, which would be expected to adversely impact coronary endothelial function in overweight patients. As mentioned previously, our data also showed that a higher level of total bilirubin in overweight patients could protect against impairment of coronary endothelial function. Thus, the relationship between total bilirubin and endothelial function may be more prominent in overweight patients.
Relationship between Total Bilirubin and HDLCholesterol
Our study showed a positive correlation between total bilirubin and HDL-C in overweight patients.
Vitek et al. 38) reported that bilirubin, total antioxidant capacity and HDL-C were significantly higher in subjects with Gilbert syndrome than in control groups. In addition, Bhuiyan et al. 31) observed that the bilirubin level was positively associated with HDL-C in young adults. Another study suggested that the protective effect of bilirubin on CHD risk is comparable to that of HDL-C 8). In line with its antioxidant properties, it is tempting to speculate that elevated bilirubin levels might protect LDL apoproteins and lipids from being oxidized, thus reducing the catabolic rate mediated by HDL receptor 39) . Thus, it is possible that the beneficial effects of bilirubin are additive or synergistic to those of HDL-C in overweight patients.
Relationship between Total Bilirubin and hs-CRP
Oxidized LDL-C is produced in arteriosclerotic lesions and compromises vascular endothelial function 40) . HDL-C can protect LDL-C against oxidation 39) , and hs-CRP is a sensitive marker of chronic inflammation occurring in arteriosclerotic lesions 41) . In addition, hs-CRP is an independent predictor of future cardiovascular events 42) . Our study demonstrated that total bilirubin was inversely correlated with hs-CRP in overweight patients. Furthermore, hs-CRP in overweight patients with lower total bilirubin was significantly higher than that in overweight patients with higher total bilirubin. These results suggest that higher bilirubin levels may contribute to an anti-inflammatory effect in overweight patients.
Several studies have described the relationship between CRP and total bilirubin. Tapan et al. 43) showed that hs-CRP was negatively correlated with total bilirubin in patients with Gilbert's syndrome. Yang et al. 44) established that hypertensive patients with carotid atherosclerosis had lower serum bilirubin and higher CRP than hypertensive patients without carotid atherosclerosis. Gonzalez et al. 45) showed that endothelial dysfunction and inflammation (increased CRP) were important indicators of vascular risk in patients with metabolic syndrome. In this context, the beneficial effects of bilirubin may be mediated by its anti-inflammatory effect in overweight patients.
Clinical Implications
The present study described the relationship between coronary endothelial function and total bilirubin and demonstrated an independent correlation between total bilirubin and hs-CRP. These data suggest that high bilirubin is associated with favorable coronary endothelial function and a lower risk of CHD, possibly via the anti-inflammatory effect of bilirubin in overweight patients without overt coronary atherosclerotic lesions. Thus, bilirubin may provide a new marker for the assessment of atherogenic risk as well as a therapeutic target for the modification of atherogenic risk. Indeed, several groups of investigators have demonstrated that weight loss therapy (either by sibutramine or via placement of an intragastric balloon) is associated with a rapid increase in total bilirubin levels and antioxidant capacity 46, 47) .
Limitations
This study has several limitations. First, our measurements were based on a single determination of total bilirubin concentration, and the time course relationship with vascular events cannot be predicted from the current study. Additionally, the methodology for coronary angiography and selective intra-coronary infusion used in this study is not amenable to establishing causality through repeat examinations. Second, the present study is cross-sectional, and its findings warrant confirmation through a prospective study. Third, because of the relatively small number of participants in our study population, further investigation involving a large number of patients with adjustment for confounding factors, such as gender or menopausal status, is required to confirm the clinical utility of total bilirubin as a marker of coronary endothelial function. Finally, the study population included only patients with normal or mildly diseased coronary arteries. Thus, the present findings may not be applicable to patients with advanced CHD.
Conclusions
This in vivo study demonstrated that high bilirubin was associated with favorable coronary endothelial function in overweight patients. Further, the anti-inflammatory effects of bilirubin may mediate this effect.
